Hope on the Horizon for Alzheimer's disease Patients
That may be about to change.
The 98 investigational medicines for Alzheimer’s disease and related dementias, either in clinical trials or awaiting FDA review, include promising prospects that target the disease’s underlying causes. Some have shown evidence of preventing new amyloid plaques from forming in the brain, while others appear to remove plaques already there.
“Right now is one of the most exciting times to be in the field Alzheimer’s disease research,” said David Morgan, PhD, CEO and director of the USF Health Byrd Alzheimer’s Institute. “Tremendous progress has been made by academic researchers, clinicians and the biopharmaceutical industry in working to come up with solutions to this memory-robbing disease.” READ MORE at UST HEALTH Read More...
Comments
USF-Byrd Alzheimer's News
21/08/10 07:53 Filed in: Alzheimer's | Alzheimer's disease research
Dr. Morgan Discusses Alzheimer’s on Fox's "Your Turn"
International Conference on Alzheimer's Disease
Alzheimer’s Institute faculty and graduate students are attending and presenting their work at the 10th annual International Conference (ICAD www.alz.org/icad).
Rules Seek to Expand Diagnosis of Alzheimer’s
13 July 2010 New York Times article New York Time Experts predict a two- to threefold increase in the number of people with the disease if new guidelines are adopted, as expected.
